PharmaEssentia Reports Near 50% YoY Revenue Growth in January

Driven by the robust global sales of Ropeginterferon alfa-2b (Ropeg), its flagship therapy for rare blood cancers, PharmaEssentia announced January revenue of NT$1.58 billion. This figure marks the second-highest monthly revenue in the company’s history, representing a 49.82% year-over-year (YoY) increase.